- Shares of Graphite Bio are down some 85% from their June 2021 IPO pricing, as its first-ever clinical trial for the treatment of sickle cell disease experienced a six-month delay.
- The company’s potentially curative technology builds on CRISPR Therapeutics by pasting a DNA template into the target gene after it has been cut.
- With no actionable data likely forthcoming until mid-2023 but trading at a significant discount to cash, the recent insider buying merited a deeper dive.
- A full investment analysis follows in the paragraphs below.
For further details see:
Graphite Bio: Selling For Much Less Than Net Cash